Dr. Jeffrey Lieberman and co-authors hypothesized that combining the xanomeline with trospium could lessen xanomeline's typical side effects in treating schizophrenia.
The Horga Lab is a psychiatry research lab that uses neuroimaging and cognitive methods to study the origins of the psychotic symptoms of schizophrenia, including hallucinations and delusions.
“Our findings open the door for the development of treatments to target specific symptoms of psychosis depending on an individual subject’s symptom profile," says Guillermo Horga, MD, PhD
Columbia Psychiatrists suggest that researchers, pharmaceutical companies, and the FDA reconsider placebo-controlled, relapse prevention studies in schizophrenia.
Dr. Jeffrey Lieberman and colleagues conclude that the time has come to cease the use of placebo in relapse prevention studies and encourage the use of active comparators.
A new study from Columbia University and New York State Psychiatric Institute offers insight into the development of delusions, which could lead to better treatments for people with psychosis.
"I expect that clinicians will change their practices by prescribing fewer benzodiazepines and more antidepressants for people with schizophrenia," Dr. T. Scott Stroup said.
“The effectiveness of combinations of antipsychotic medications remains unclear; reviews of this treatment strategy agree on the need for further investigation,” Dr. T. Scott Stroup and team wrote.
Patients with schizophrenia are often treated with more than one type of psychiatric medication, but a new study suggests that some combinations may be more effective than others.
Researchers at Columbia have developed a “Cascade of Care” model for treating individuals with opioid use disorder based on lessons learned in the HIV/AIDS field.
Dr. Terry Goldberg sounded some notes of caution regarding a study that questions whether certain cholesterol, blood pressure and diabetes drugs could help manage mental illnesses like schizophrenia.